ALBO News and Press, Albireo Pharma Inc. From 08/07/20

Image source: The Motley Fool. Albireo Pharma, Inc.   (NASDAQ: ALBO) Q2 2020 Earnings Call Aug 7, 2020 , 10:00 p.m. ET Operator Continue reading

Albireo Pharma (NASDAQ: ALBO ) : Q2 GAAP EPS of -$1.38 beats by $0.28 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials — —  Enrolled first biliary atresia patients in second odevixibat pivotal study — —  Completed two financing transactions to secure cash into beginning of 2022 — ...

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat pres...

—  Conference call and webcast to be held at 10:00 a.m. ET —  BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that ma...

BOSTON, July 20, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the launch of an Expanded Access Program (EAP) for investigational lead product candidate odevixibat,...

Galera Therapeutics Advances Mid Stage Clinical Trial of GC4419 Galera Therapeutics Inc. ( GRTX ) reported that it has completed the process of patient enrollment for its Phase 1b/2a clinical trial of avasopasem manganese or GC4419. The drug candidate is being assessed for safety and ant...

Albireo Pharma ( ALBO +1.9% ) has enrolled  first patient in global Phase 3 trial (BOLD) of odevixibat for biliary atresia, expanding the development of odevixibat to a second rare cholestatic liver disease indication. More news on: Albireo Pharma, Inc., Healthcare stocks news,...

— BOLD is first-ever pivotal trial for biliary atresia — — Trial expands odevixibat’s development program into second rare cholestatic liver disease — BOSTON, July 14, 2020 (GLOBE NEWSWIRE) --  Albireo Pharma, Inc. (Nasdaq: ALBO), a ...

There's a number of upcoming catalysts in the liver disease treatment space, prompting Needham to update its takes on drugmakers targeting the diseases. More news on: Intercept Pharmaceuticals, Inc., Albireo Pharma, Inc., Mirum Pharmaceuticals, Inc., Healthcare stocks news, Notable Calls ...